Abstract 294P
Background
Cancer patients are living longer with early detection and improved treatment. When combined with conventional therapy, complementary and alternative medicine (CAM) might help patients manage cancer symptoms and treatment toxicities. Ayurveda, Yoga Naturopathy, Unani, Siddha, and Homeopathy (AYUSH) are native to India, and widely practiced, yet, their association with cancer-related distress is unknown.
Methods
From March to June 2022, cancer patients attending OPD, IPD, and Daycare services at AIIMS Rishikesh responded to a patient health questionnaire (PHQ-9), along with a locally developed and validated questionnaire about knowledge, attitude, practices (KAP) of CAM. Bivariate and multivariate analyses were performed to ascertain the levels of depression/distress, KAP-related outcomes of CAM among cancer patients.
Results
556 cancer patients with a mean age of 48.59 ± 14.82 years (286 males, 270 females) were included. 393 respondents (70.7%) had never used CAM, while 163 (29.3%) had. 342 (61.5%) participants said they would choose CAM if their condition became untreatable, 129 (23.2%) wouldn't, 85 (15.3%) were not sure. Use of CAM was correlated with cancer stage (C 0.104, p 0.045) (ρ .098, p .020). Individuals with stage 4 cancer were more likely to have used CAM (p .029, OR 1.719, CI 1.059 ± 2.792). Multinomial linear regression showed that metastatic cancer tends to have more severe depression (p .022, OR 3.900, CI 1.218 ± 12.490). The level of education was inversely related to beliefs about CAM's effectiveness in curing cancer (C .185, p .012 & ρ -0.12, p .004) and its safety with fewer adverse reactions than modern medicine (C .197, p .004 & ρ -.124, p .003). Among AYUSH modalities, 212 (38.1%) chose Yoga, 186 (33.5%) Ayurveda, 45 (8.1%), Unani, 19 (3.4%), Siddha, and 173 (31.1%) chose others.
Conclusions
Terminally ill patients used CAM more, advanced-stage cancer patients had higher depression scores. People with lower educational status believe in CAM more.Yoga was the most preferred CAM. CAM can aid in improving cancer therapy tolerance and end-of-life care but specific CAM especially yoga protocols can be developed to help in these situations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
281P - Cancer-related symptoms as mediators between treatment and functional capacity in adolescents and young adults (AYAs) with cancer
Presenter: Chung Tin Justin Ma
Session: Poster viewing 04
282P - Nutritional status and nutritional therapy of common cancer in a cancer hospital of Southwest China
Presenter: Huiqing Yu
Session: Poster viewing 04
283P - Comparative analysis of osteoporotic fracture (OF) and pathologic fracture (PF) in patients with metastatic colorectal cancer (mCRC) who received palliative chemotherapy
Presenter: Yejee Lim
Session: Poster viewing 04
284P - Gut microbiota mediates the protective effects of resveratrol against the intestinal barrier dysfunction in non-alcoholic steatohepatitis induced by high-fat diet
Presenter: Haoyang Cao
Session: Poster viewing 04
285P - Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients
Presenter: Aditya Sarin
Session: Poster viewing 04
286P - Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response
Presenter: Amy Body
Session: Poster viewing 04
287P - Long-term yoga enhances the quality of life and symptomatic scale in breast cancer patients undergoing treatment
Presenter: Mayank Jain
Session: Poster viewing 04
288P - Impact of hormonal contraception on estradiol and progesterone serum levels: A 6-year study on progression-free survival, disease-free survival, and overall survival at Dr. Moewardi Hospital
Presenter: Widyanti Soewoto
Session: Poster viewing 04
289P - Cancer cachexia following breast cancer (BC) chemotherapy was associated with clinical stage, number of chemotherapy cycles, and vitamin D concentration
Presenter: Susanna Hutajulu
Session: Poster viewing 04
290P - Use of PEG G-CSF is associated with decreased myelotoxicity in dexrazoxane-used aggressive non-Hodgkin lymphoma patients
Presenter: Sung-Nam Lim
Session: Poster viewing 04